According to the latest report from the AACR, breast cancer cases are expected to increase by 50% by 2030. Lack of early and accurate detection poses a significant challenge in diagnosis and treatment. Currently, in the US, 45 million mammograms are performed annually, followed by more than 4 million call-backs due to the lack of unequivocal detection. The total cost for re‑testing is roughly $1.2B per year. There is a strong need for earlier and more accurate detection of breast cancer. A solution to this problem will not only have a significant impact on patient health, but will also help to drive down health care costs. 
Technology Overview
The proposed multi-modal system operates in a similar two-step fashion. In the first step, the breast is placed under clinical compression, and the T2-DBT measurements are recorded using low-dosage X-rays. In the second step, the mechatronics system, which contains T1-NRI, T3-US and T4-TA probes immersed in a bolus fluid, is mechanically scanned over the same breast that is kept under clinical compression. Once the data is collected, a joint 3D reconstruction of the biophysical parameters of the breast is performed.
- CM-BCS is fast and accurate, reporting on nine constitutive breast features. 
- The combined CM-BCS uses a-priori information to achieve a near-optimal first guess, allowing for the imaging algorithm to converge to the right solution.
- Collects data in (2D) outside a linear trajectory enhancing the 3D focusing capabilities of the system.
- Breast imaging market
- License
- Research collaboration 
- Licensing
Patent Information:
For Information, Contact:
Mark Saulich
Associate Director of Commercialization
Northeastern University
Jose Angel Martinez-Lorenzo
Richard Obermeier
Ashkan Ghanbarzadeh
Ali Molaei
Juan Heredia Juesas